Recombinant Goat Spectrin beta chain, brain 1

What is Spectrin beta chain, brain 1 (SPTBN1) and what are its primary functions in cellular biology?

Spectrin beta chain, brain 1 (SPTBN1), also known as βII-spectrin, is a non-erythrocytic member of the spectrin family that functions as a critical component of the membrane-associated cytoskeletal network. It serves as an actin crosslinking and molecular scaffold protein that links the plasma membrane to the actin cytoskeleton . SPTBN1 plays essential roles in:

• Determining and maintaining cell shape

• Arranging transmembrane proteins

• Organizing cellular organelles

• Regulating cell proliferation and liver regeneration

• Mediating TGF-β signaling pathway components

• Controlling G1/S cell cycle transition through interactions with cell cycle checkpoint proteins

The protein contains an N-terminal actin-binding domain and 17 spectrin repeats involved in dimer formation with alpha-spectrin to create functional heterotetramers .

How does SPTBN1 expression vary across different tissues in mammals?

Expression patterns of SPTBN1 exhibit tissue-specific distribution across mammalian species:

While specific goat SPTBN1 expression patterns may vary slightly from other mammals, comparative analysis suggests conservation of these general expression patterns across species .

How do I optimize storage conditions for recombinant SPTBN1 to maintain protein stability?

For optimal stability of recombinant SPTBN1:

• Store the protein at -80°C for long-term storage

• Avoid repeated freeze-thaw cycles which can significantly reduce protein activity

• For working solutions, store in buffer containing:

  • 50 mM Tris-HCl

  • 10 mM reduced glutathione

  • pH 8.0

• Consider adding glycerol (50%) and small amounts of sodium azide (0.02%) for improved stability

• For experiments requiring prolonged incubation at room or physiological temperatures, supplement storage buffer with protease inhibitors

• Aliquot stocks to minimize freeze-thaw cycles

• Validate protein stability by periodic SDS-PAGE analysis (>80% purity should be maintained)

What expression systems are most effective for producing functional recombinant goat SPTBN1 protein?

Several expression systems can be used for recombinant goat SPTBN1 production, each with distinct advantages:

For goat SPTBN1, mammalian expression systems are particularly recommended for studies investigating protein interactions with TGF-β pathway components or other signaling partners, as these interactions may depend on specific post-translational modifications .

What purification strategies maximize yield and maintain functional integrity of recombinant SPTBN1?

A multi-step purification approach is recommended for high-purity, functional SPTBN1:

• Initial capture:

  • For GST-tagged proteins: Use glutathione beads in PBEP buffer (PBS with 5 mM EDTA and 1 mM PMSF)

  • Wash with ≥10 bed volumes of buffer

• Tag removal:

  • For GST-tagged constructs, use thrombin at empirically determined ratios

  • Stop reaction with 300 μM PMSF

• Secondary purification:

  • Re-application to glutathione beads to remove cleaved GST

  • Size exclusion chromatography using Superdex 75 column for removal of residual contaminants

• Quality control:

  • Verify mass by MALDI analysis

  • Assess purity by SDS-PAGE (aim for >80%)

• Buffer optimization:

  • Final buffer: 50 mM Tris-HCl (pH 8.0), 10 mM reduced glutathione, with optional 1 mM β-mercaptoethanol

This methodology has demonstrated successful purification of functional spectrin fragments while maintaining their native binding properties .

How can I accurately assess the binding interaction between recombinant SPTBN1 and its partners in vitro?

Several complementary approaches can be used to characterize SPTBN1 binding interactions:

• Yeast two-hybrid (Y2H) assays:

  • Design spectrin fragments encompassing the CH2 domain (except its inhibitory first α-helix), SR1 domain, and linker between them

  • Test binding with 3-AT resistance up to 100 mM for strong interactions

  • Include controls such as Smad/Smurf interactions for comparison

• Co-immunoprecipitation assays:

  • Use anti-Flag antibodies with recombinant Flag-tagged SPTBN1 to pull down interaction partners

  • Validate with Western blot analysis using antibodies against expected binding partners

  • Test interactions with partners like α-spectrin and Duf-GFP

• Surface Plasmon Resonance (SPR):

  • Immobilize purified SPTBN1 on sensor chips

  • Measure binding kinetics and affinity constants for various partners

  • Compare wild-type versus mutant binding properties

• Fluorescence Recovery After Photobleaching (FRAP):

  • Assess reduced mobility of SPTBN1 when incorporated into membrane-associated periodic skeleton (MPS)

  • Compare with non-incorporated controls to evaluate functional incorporation

What are the optimal conditions for studying SPTBN1's role in TGF-β signaling pathways?

To effectively study SPTBN1's function in TGF-β signaling:

• Cell model selection:

  • Hepatocellular carcinoma (HCC) cells show strong SPTBN1-TGF-β pathway interactions

  • Other suitable models: primary hepatocytes, cardiomyocytes

• Experimental conditions:

  • Stimulate cells with TGF-β1 (5-10 ng/ml) for 24-48 hours

  • Monitor cell proliferation inhibition

  • For cell cycle analysis, synchronize cells before TGF-β1 treatment

• Key readouts:

  • Measure expression of:

    • Cyclin-dependent kinase 4 (CDK4)

    • Cyclin D1

    • Retinoblastoma protein (Rb)

    • Smad proteins (particularly translocation to nucleus)

• Controls:

  • SPTBN1 overexpression vs. knockdown

  • Inhibition of TGF-β signaling with specific inhibitors

  • Non-TGF-β pathway controls to establish specificity

SPTBN1 has been shown to play a crucial role in the translocation of Smads, and its loss causes G1/S phase transition due to activation of cyclin D1/CDK4 in hepatocellular carcinoma cells .

How can I use CRISPR/Cas9 to effectively study SPTBN1 function in neuronal development models?

For CRISPR/Cas9-mediated investigation of SPTBN1:

• Guide RNA design:

  • Target conserved exons present in all SPTBN1 isoforms (exons 2 or 8 are effective targets)

  • Design 2 guide RNAs to increase knockout efficiency

  • Validate guide RNA efficiency using prediction tools

• Delivery methods:

  • For in vivo studies: in utero electroporation (IUE) of CRISPR/Cas9 constructs to neural progenitors

  • Co-deliver GFP plasmid to track transfected cells

  • For in vitro: nucleofection or lipofection into primary neurons or neuronal cell lines

• Validation of knockout efficiency:

  • FACS isolation of GFP-positive cells

  • Next-generation sequencing of amplicons spanning CRISPR cut sites (aim for >40% out-of-frame indels)

  • Immunostaining for SPTBN1 protein in dissociated cells (expect <20% positive cells in successful knockouts)

• Phenotypic analysis:

  • Assess neuronal morphology, branching patterns, and dendrite development

  • Evaluate changes in synaptogenesis and axonal development

  • Monitor cell cycle progression and potential apoptosis

This approach has successfully demonstrated critical roles of spectrin in dendritic and axonal development and synaptogenesis .

How do SPTBN1 mutations affect the nanoscale organization of the neuronal membrane-associated periodic skeleton (MPS)?

To investigate SPTBN1's role in MPS organization:

• High-resolution imaging techniques:

  • Use stimulated emission depletion (STED) nanoscopy for visualization of MPS components

  • Apply two-color STED to observe co-localization with other MPS proteins

  • Image both wild-type and mutant/overexpressed SPTBN1 variants

• Quantification methods:

  • Apply 2D autocorrelation (AC) analysis to detect repeating patterns (periodicity ~190 nm is characteristic of MPS components)

  • Use cross-correlation (CC) analysis to determine phase relationships with other MPS proteins

  • Measure fluorescent signal intensity along axonal regions to correlate protein levels with periodicity

• Experimental manipulations:

  • Compare wild-type vs. phosphomimetic SPTBN1 variants (e.g., mutations of serine/threonine residues to glutamate)

  • Assess different splice variants (full-length vs. alternatively spliced forms)

  • Study developmental stages to identify temporal changes in MPS organization

Research has shown that SPTBN1 overexpression can enhance the periodicity of MPS without altering MPS protein concentrations, suggesting a role in organizing rather than recruiting proteins to the MPS .

What methodologies are effective for studying the mechanical properties of SPTBN1 in membrane stabilization?

To investigate SPTBN1's biomechanical functions:

• Membrane tension measurements:

  • Use optical tweezers to apply controlled forces to membrane tethers

  • Compare membrane resistance in cells with normal vs. altered SPTBN1 levels

  • Measure force-extension curves to determine membrane stiffness parameters

• Atomic Force Microscopy (AFM):

  • Probe cell surface mechanics with varying SPTBN1 expression

  • Map elastic modulus across cell surface to identify SPTBN1-enriched domains

  • Apply controlled mechanical stress and observe recovery responses

• Molecular dynamics simulations:

  • Model the impact of mutations (e.g., R1098Q) on spectrin structural integrity

  • Simulate spectrin repeats under tension to predict breaking points

  • Compare wild-type and mutant spectrin behavior under mechanical stress

• Live-cell mechanical challenges:

  • Apply microfluidic-based constrictions or shear stress

  • Compare membrane integrity and recovery in cells with modified SPTBN1

  • Correlate mechanical resilience with SPTBN1 expression levels and localization

These approaches have revealed that spectrin networks function as membrane organizers and stabilizers, adapting to mechanical stress and providing resilience to cells .

How can recombinant SPTBN1 be used to study its tumor suppressor function in cancer models?

To investigate SPTBN1's tumor suppressor role:

• Cell line models:

  • Compare SPTBN1 expression in matched normal/tumor cell lines

  • Create stable SPTBN1 overexpression and knockdown cell lines

  • Focus on hepatocellular carcinoma, pancreatic cancer, and other GI tract malignancies

• Key experimental readouts:

  • Cell proliferation assays (BrdU incorporation, Ki-67 staining)

  • Cell cycle analysis (flow cytometry for G1/S transition)

  • TGF-β pathway activation (Smad phosphorylation and nuclear translocation)

  • Expression of cell cycle regulators (cyclin D1, CDK4, Rb phosphorylation)

• Animal models:

  • Xenograft models with SPTBN1-modulated cancer cells

  • Tissue-specific knockout using Cre-loxP systems

  • Correlation of tumor growth, invasion, and metastasis with SPTBN1 status

• Patient sample analyses:

  • Immunohistochemistry for SPTBN1 in tumor microarrays

  • Correlation with patient survival and clinical parameters

  • Integration with genomic data on SPTBN1 mutations/alterations

Reduced expression of SPTBN1 has been found to correlate with shorter survival in hepatocellular cancer, pancreatic cancer, and other gastrointestinal malignancies, supporting its tumor suppressor function .

What approaches are most effective for studying SPTBN1's role in neurodegenerative disorders?

To investigate SPTBN1 in neurodegeneration:

• Animal model generation:

  • Create conditional knockouts using brain region-specific promoters

  • Develop knock-in models with specific mutations (e.g., R1098Q)

  • Monitor phenotype progression from neonatal to adult stages

• Histological analysis:

  • Assess brain morphology at different developmental stages

  • Quantify neuronal loss in affected regions (e.g., Purkinje cells in cerebellum)

  • Measure changes in dendrite morphology and planar orientation

• Protein-level analysis:

  • Compare expression patterns of SPTBN1 and other spectrin isoforms

  • Assess spectrin proteolysis susceptibility (particularly by calpain)

  • Evaluate interactions with calcium-binding proteins like calmodulin

• Functional assessments:

  • Behavioral testing for motor coordination (rotarod, balance beam)

  • Electrophysiological recordings to assess neuronal function

  • Time-course analysis to correlate molecular changes with symptom progression

Studies with the R1098Q spectrin variant revealed progressive cerebellar degeneration correlating with decline in coordinated movement, with dramatic changes in Purkinje cell morphology and number (>80% reduction by 26 weeks) .

How does SPTBN1 interact with the axon initial segment and nodes of Ranvier, and what methodologies best investigate these roles?

To study SPTBN1's function at specialized neuronal domains:

• Subcellular localization studies:

  • Use super-resolution microscopy to visualize SPTBN1 at nodes of Ranvier

  • Co-immunostaining with nodal (Nav channels), paranodal (Caspr, Contactin), and juxtaparanodal (Kv channels) markers

  • Track SPTBN1 localization during node formation and maintenance

• Molecular interaction analysis:

  • Identify binding partners at nodes using proximity labeling approaches (BioID, APEX)

  • Perform co-immunoprecipitation with nodal/AIS components

  • Map binding domains through deletion/mutation analysis

• Functional manipulations:

  • Conditional knockout in specific neuronal populations

  • Acute protein knockdown using inducible systems

  • Live imaging of node assembly and maintenance with fluorescently tagged proteins

• Electrophysiological assessment:

  • Measure conduction velocity in spectrin-deficient axons

  • Assess ion channel clustering and function at nodes

  • Correlate structural changes with functional deficits

Research has demonstrated that β4-spectrins are essential for membrane stability and molecular organization of the nodes of Ranvier, with knockout animals showing altered nodes and paranodes during CNS development .

What are the most common challenges in generating specific antibodies against goat SPTBN1 and how can they be overcome?

Challenges and solutions for goat SPTBN1 antibody production:

• High conservation between species:

  • Select peptide immunogens from less conserved regions

  • Use recombinant protein fragments rather than synthetic peptides

  • Validate cross-reactivity against multiple species before use

• Large protein size (~275 kDa):

  • Target specific domains (e.g., the CH2 domain, SR1 domain)

  • Generate antibodies against multiple epitopes and validate independently

  • Use recombinant fragments of manageable size (200-250 amino acids)

• Multiple isoforms:

  • Design immunogens to either target all isoforms or be isoform-specific

  • Carefully sequence and verify the goat-specific sequences

  • Validate antibody specificity against multiple isoforms

• Validation strategies:

  • Use western blotting with positive controls (brain, kidney lysates)

  • Include knockout/knockdown samples as negative controls

  • Test in immunoprecipitation, immunohistochemistry, and immunofluorescence applications

  • Verify expected molecular weight (approximately 275 kDa)

Available antibodies like those against the human or mouse SPTBN1 should be tested for cross-reactivity with goat SPTBN1 before use in experimental applications .

What are the most effective experimental designs for distinguishing between different beta-spectrin isoforms in functional studies?

Strategies to differentiate between beta-spectrin isoforms:

• Isoform-specific knockdown/knockout:

  • Design siRNAs or CRISPR guides targeting unique regions of each isoform

  • Validate knockdown specificity by qPCR and western blot

  • Include rescue experiments with resistant constructs

• Expression pattern analysis:

  • Use isoform-specific antibodies in tissue sections

  • Compare expression in different cell types and subcellular compartments

  • Create expression maps across developmental stages

• Functional domain mapping:

  Beta-Spectrin Isoform	Distinctive Features	Detection Method	Typical Expression
  β1 (erythrocytic)	Moderate H2H binding affinity (Kd = 400-800 nM)	Western blot, isoform-specific antibodies	Erythrocytes
  β2 (SPTBN1)	High H2H binding affinity (Kd = 4.5-8.5 nM), TGF-β pathway interaction	Anti-SPTBN1 antibodies, molecular weight ~275 kDa	Brain, liver, kidney, broadly expressed
  β3 (SPTBN2)	Stabilizes glutamate transporter EAAT4, mutations cause SCA5	Anti-SPTBN2 antibodies, molecular weight varies by isoform	Cerebellum (Purkinje cells), brain
  β4 (SPTBN4)	Essential for nodes of Ranvier, localized to nuclear matrix	Anti-SPTBN4 antibodies, molecular weight >200 kDa	Brain, pancreatic islets

• Functional rescue experiments:

  • Knockdown endogenous spectrins and express individual isoforms

  • Test ability of each isoform to rescue specific cellular functions

  • Create chimeric proteins to map functional domains

These approaches have been used to demonstrate distinct roles for different beta-spectrin isoforms in neuronal development, axon initial segment formation, and nodal organization .